<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03706911</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-VM1500ALAI-01</org_study_id>
    <nct_id>NCT03706911</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects</brief_title>
  <official_title>Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viriom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viriom</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate safety, tolerability and pharmacokinetics of VM-1500A-LAI single
      and multiple ascending doses in healthy subjects. The study will be conducted in 1
      investigational site in Russia in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study to evaluate safety, tolerability and pharmacokinetics of a long-acting
      injectable NNRTI VM-1500A-LAI single and multiple ascending doses in healthy subjects. The
      study will be conducted in 1 investigational site in Russia in healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2018</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of AEs and SAEs</measure>
    <time_frame>4 weeks for SAD, 8 weeks for MAD</time_frame>
    <description>The incidence of adverse events (AEs) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>concentration of VM1500A in plasma</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of VM1500A in BFE</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of VM1500A in PBMC</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>VM-1500A-LAI 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI 50mg IM single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI 150mg IM single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI 300mg IM single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI 600mg IM single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI 1200mg IM single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI XXX5mg Multiple</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI selected dose IM, 2 injections monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500A-LAI XXX6mg Multiple</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500A-LAI double selected dose IM, 2 injections monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VM-1500A-LAI</intervention_name>
    <description>VM1500A (parent drug of elsulfavirine) IM injection dosage form</description>
    <arm_group_label>VM-1500A-LAI 1200mg</arm_group_label>
    <arm_group_label>VM-1500A-LAI 150mg</arm_group_label>
    <arm_group_label>VM-1500A-LAI 300mg</arm_group_label>
    <arm_group_label>VM-1500A-LAI 50mg</arm_group_label>
    <arm_group_label>VM-1500A-LAI 600mg</arm_group_label>
    <arm_group_label>VM-1500A-LAI XXX5mg Multiple</arm_group_label>
    <arm_group_label>VM-1500A-LAI XXX6mg Multiple</arm_group_label>
    <other_name>VM1500A-LAI</other_name>
    <other_name>VM1500A</other_name>
    <other_name>VM-1500A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-smoking healthy male subjects between the ages of 18 and 45 years (inclusive);

          2. Verified diagnosis of &quot;healthy&quot; according to standard clinical, laboratory and
             instrumental examination methods;

          3. Body weight ≥ 50 kg and Body Mass Index from 18.5 to 30.0 kg/m2;

          4. Signed the Participant Explanation Sheet and the Informed Consent Form; Consent to use
             an adequate double method of contraception throughout the study and 3 months after its
             completion in the form of a condom with spermicide (in the form of cream, jelly, foam)

        Exclusion Criteria:

          1. Chronic diseases of cardiovascular, bronchopulmonary, neuroendocrine, musculoskeletal
             system and gastrointestinal tract, as well as immunologic, liver, kidneys, blood
             diseases;

          2. Deviations of laboratory parameters from normal values at screening (the acceptable
             limits of laboratory parameters are specified in Annex 1), as well as deviations from
             the normal values on the ECG results;

          3. Systolic pressure less than 90 mm Mercury or above 130 mm Mercury, diastolic pressure
             less than 60 mm Mercury or above 85 mm Mercury, heart rate less than 60 BPM or more
             than 90 BPM at screening;

          4. Regular intake of drugs less than 2 weeks prior to screening (including herbal
             preparations and dietary supplements); intake of drugs that have a pronounced effect
             on hemodynamics, liver, kidney and CNS function and etc. (for example, barbiturates,
             omeprazole, cimetidine, etc.) less than 4 weeks prior to screening;

          5. Presence of antibodies to HIV and hepatitis C virus, presence of hepatitis В surface
             antigen, a positive syphilis test;

          6. Presence of an unstable sleep structure (for example, night work, sleep disturbances,
             insomnia, recent return from another time zone, etc.);

          7. Signs of alcohol (taking more than 10 units of alcohol per week ) or drug addiction;
             alcohol or drugs consumption within 7 days prior to screening; cigarettes smoking 3
             months prior to screening; positive drug and alcohol test at screening;

          8. Presence of depression episodes or other mental disorders/conditions that require
             medical therapy in history;

          9. Burdened allergic medical history (including drug intolerance and food allergy);

         10. Blood/plasma donation (450 ml of blood or plasma and more) less than 12 months prior
             to screening, surgery;

         11. Presence of diseases and conditions in the present or past, including surgery, which,
             according to the Investigator, may affect the absorption, distribution, metabolism or
             excretion of the study drug;

         12. Participation in other clinical studies or taking other study drugs 3 months before
             screening;

         13. Acute infectious diseases less than 4 weeks prior to screening;

         14. Incapable of reading or writing; no desire to understand and adhere to the study
             protocol procedures; non-compliance with the drugs intake regimen or execution of
             procedures, which as the Investigator may think may affect the study results or
             subject's safety and prevent the subject from further participation in the study; any
             other associated medical or serious psychological conditions making the subject not
             eligible to participate in the clinical study, restricting legality of obtaining the
             informed consent or affecting the subject's ability to take part in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Smolyarchuk, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>I.M. Sechenov First Moscow State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Yakubova, PhD</last_name>
    <phone>+7 (495) 995-49-44</phone>
    <email>ey@chemrar.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vladimir Kan, PhD</last_name>
    <phone>7 (495) 995-49-44</phone>
    <email>vkan@chemrar.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>I.M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119146</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <last_name>Elena Smolyarchuk, PhD</last_name>
      <phone>+7 499 248 6479</phone>
    </contact>
    <investigator>
      <last_name>Elena Smolyarchuk, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

